UK's Poor Uptake Of New Drugs May Be Hitting Clinical Trial Investment
Executive Summary
The pharmaceutical industry wants the UK to improve its uptake of innovative medicines in order to spur investment in clinical trials under the government's life sciences sector deal. One industry representative says companies are already questioning the ethics of conducting trials in a country where their drug might not be commercialized.